Cologuard – pro
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences’ prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. It is included in the colorectal cancer screening guidelines of the U.S. Preventive Services Task Force, American Cancer Society and stool DNA is listed in the screening guidelines of the U.S. Multi-Society Task Force on Colorectal Cancer. Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer.
References
1.Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287-1297.
2.Centers for Disease Control and Prevention (CDC). Cancer screening — United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:41-45.
3.US Preventive Services Task Force. Screening for colorectal cancer. Rockville, Md: US Preventive Services Task Force; 2008. http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm
4.Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol. 2009;104:739-750.